LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia

Photo by nci from unsplash

ing manifestations related to RA from those of SCD in patients with joint complaints, independently of the genotype or severity of complications of SCD. It is strongly advised to keep… Click to show full abstract

ing manifestations related to RA from those of SCD in patients with joint complaints, independently of the genotype or severity of complications of SCD. It is strongly advised to keep in mind the possibility of RA coexistence when the clinical course of the painful crisis in SCD patients does not follow the expected trajectory. The prompt use of agents which target the underlying pathophysiology of RA remains the best option for the prevention of potential damage in these patients, who usually present with comorbidities due to SCD.

Keywords: effects daratumumab; cell acute; clinical effects; acute lymphoblastic; immunomodulatory clinical; daratumumab cell

Journal Title: British Journal of Haematology
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.